Targeting B cells in systemic lupus erythematosus: Not just déjà vu all over again

Arthritis Research and Therapy

Volumn 8, Issue 3, 2006, Pages

  Eisenberg, Robert ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CD22 ANTIGEN; CELL MARKER; EPRATUZUMAB; RITUXIMAB; MONOCLONAL ANTIBODY;

ANTIGEN RECOGNITION; B LYMPHOCYTE; CELL ACTIVITY; CLINICAL TRIAL; DOWN REGULATION; DRUG BINDING SITE; DRUG EFFICACY; DRUG SAFETY; GENE TARGETING; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE DEPLETION; LYMPHOMA; NONHUMAN; NOTE; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; REPRODUCIBILITY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; B-LYMPHOCYTES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; REPRODUCIBILITY OF RESULTS; SIALIC ACID BINDING IG-LIKE LECTIN 2; TREATMENT OUTCOME;

EID: 33745235515     PISSN: 14786354     EISSN: None     Source Type: Journal    
DOI: 10.1186/ar1967     Document Type: Note

References (12)

1. Dörner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006, 8:R74.
2. Tedder TF, Poe JC, Haas KM: CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv Immunol 2005, 88:1-50.
3. Eisenberg R, Looney RJ: The therapeutic potential of anti-CD20 'what do B-cells do?'. Clin Immunol 2005, 117:207-213.
4. Leonard JP, Coleman M, Ketas JC, Chadburn A, Ely S, Furman RR, Wegener WA, Hansen HJ, Ziccardi H, Eschenberg M, et al.: Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 2003, 21:3051-3059.
5. Otipoby KL, Andersson KB, Draves KE, Klaus SJ, Farr AG, Kerner JD, Perlmutter RM, Law CL, Clark EA: CD22 regulates thymus-independent responses and the lifespan of B calls. Nature 1996, 384:634-637.
6. O'Keefe TL, Williams GT, Batista FD, Neuberger MS: Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J Exp Med 1999, 189:1307-1313.
7. Mary C, Laporte C, Parzy D, Santiago ML, Stefani F, Lajaunias F, Parkhouse RM, O'Keefe TL, Neuberger MS, Izui S, et al.: Dysregulated expression of the Cd22 gene as a result of a short interspersed nucleotide element insertion in Cd22a lupus-prone mice. J Immunol 2000, 165:2987-2996.
8. Hatta Y, Tsuchiya N, Matsushita M, Shiota M, Hagiwara K, Tokunaga K: Identification of the gene variations in human CD22. Immunogenetics 1999, 49:280-286.
9. Carnahan J, Wang P, Kendall R, Chen C, Hu S, Boone T, Juan T, Talvenheimo J, Montestruque S, Sun J, et al.: Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res 2003, 9:3982S-3990S.
10. 186Reepratuzumab for the treatment of patients with non-Hodgkin's lymphoma. Clin Cancer Res 2003, 9:3995S-4002S.
11. Leonard JP, Coleman M, Ketas J, Ashe M, Fiore JM, Furman RR, Niesvizky R, Shore T, Chadburn A, Horne H, et al.: Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 2005, 23: 5044-5051.
12. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I: B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004, 50: 2580-2589.